← Back to Screener
TScan Therapeutics, Inc. Common Stock (TCRX)
Price$1.43
Favorite Metrics
Price vs S&P 500 (26W)-54.90%
Price vs S&P 500 (4W)4.93%
Market Capitalization$67.71M
All Metrics
Book Value / Share (Quarterly)$2.16
P/TBV (Annual)2.46x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-8.64%
Cash Flow / Share (Quarterly)$-2.46
Price vs S&P 500 (YTD)14.86%
Net Profit Margin (TTM)-1256.81%
EPS (TTM)$-1.00
10-Day Avg Trading Volume1.71M
EPS Excl Extra (TTM)$-1.00
Revenue Growth (5Y)56.78%
EPS (Annual)$-1.00
ROI (Annual)-83.37%
Net Profit Margin (5Y Avg)-1435.40%
Cash / Share (Quarterly)$2.68
Revenue Growth QoQ (YoY)286.02%
ROA (Last FY)-56.72%
Revenue Growth TTM (YoY)266.65%
EBITD / Share (TTM)$-1.02
ROE (5Y Avg)-62.86%
Operating Margin (TTM)-1315.38%
Cash Flow / Share (Annual)$-2.46
P/B Ratio0.55x
P/B Ratio (Quarterly)0.46x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)-5.05x
ROA (TTM)-46.25%
EPS Incl Extra (Annual)$-1.00
Current Ratio (Annual)8.41x
Quick Ratio (Quarterly)8.15x
3-Month Avg Trading Volume0.69M
52-Week Price Return-8.46%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.53
P/S Ratio (Annual)6.56x
Asset Turnover (Annual)0.05x
52-Week High$2.57
Operating Margin (5Y Avg)-1511.52%
EPS Excl Extra (Annual)$-1.00
CapEx CAGR (5Y)0.78%
26-Week Price Return-46.15%
Quick Ratio (Annual)8.15x
13-Week Price Return-0.83%
Total Debt / Equity (Annual)0.26x
Current Ratio (Quarterly)8.41x
Enterprise Value$-52.159
Revenue / Share Growth (5Y)11.49%
Asset Turnover (TTM)0.04x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1256.81%
Cash / Share (Annual)$2.68
3-Month Return Std Dev62.35%
Net Income / Employee (TTM)$-1
ROE (Last FY)-105.40%
EPS Basic Excl Extra (Annual)$-1.00
Total Debt / Equity (Quarterly)0.26x
EPS Incl Extra (TTM)$-1.00
ROI (TTM)-66.25%
P/S Ratio (TTM)6.56x
Pretax Margin (5Y Avg)-1435.40%
Revenue / Share (Annual)$0.08
Tangible BV / Share (Annual)$4.10
Price vs S&P 500 (52W)-43.56%
Year-to-Date Return19.00%
5-Day Price Return16.67%
EPS Normalized (Annual)$-1.00
ROA (5Y Avg)-36.59%
Net Profit Margin (Annual)-1256.81%
Month-to-Date Return17.82%
Cash Flow / Share (TTM)$-1.74
EBITD / Share (Annual)$-1.02
Operating Margin (Annual)-1315.38%
LT Debt / Equity (Annual)0.26x
ROI (5Y Avg)-52.22%
LT Debt / Equity (Quarterly)0.26x
EPS Basic Excl Extra (TTM)$-1.00
P/TBV (Quarterly)1.45x
P/B Ratio (Annual)0.46x
Pretax Margin (TTM)-1256.81%
Book Value / Share (Annual)$2.16
Price vs S&P 500 (13W)-3.70%
Beta1.14x
Revenue / Share (TTM)$0.08
ROE (TTM)-79.36%
52-Week Low$0.88
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TCRXTScan Therapeutics, Inc. Common Stock | 6.56x | 266.65% | — | — | $1.43 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
TScan Therapeutics is a clinical-stage biotech company developing T cell receptor (TCR)-engineered T cell therapies to treat cancer. Its pipeline includes TSC-100 and TSC-101, liquid tumor candidates designed to eliminate residual leukemia and prevent relapse following hematopoietic stem cell transplantation, plus multiplexed TCR-T candidates for solid tumors.